Similarly, in the phase III NEJ026 trial, no patients developed ILD in the bevacizumab (an anti-VEGF monoclonal antibody) plus erlotinib arm, compared with 4% in the erlotinib monotherapy arm [41]. This evidence concerns the gene VEGFA and interstitial lung disease.